The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: A retrospective study

Biomedicine and Pharmacotherapy

Volumn 66, Issue 4, 2012, Pages 279-284

  Chen, X F ^a   Wang, R ^a   Yin, Y M ^a   Roe O D ^b,c   Li, J ^a   Zhu, L J ^a   Guo, R H ^a   Wu, Ting ^a   Shu, Y Q ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c Levanger Hospital   (Norway)

Author keywords

Monosialotetrahexosylganglioside; Neurotoxicity; Oxaliplatin

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GANGLIOSIDE GM1; OXALIPLATIN;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHRONIC TOXICITY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROPROTECTION; NEUROTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; G(M1) GANGLIOSIDE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84862811136     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.01.002     Document Type: Article

References (43)

1. Kweekel D.M., Gelderblom H., Guchelaar H.J. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 2005, 31:90-105.
2. Land S.R., Kopec J.A., Cecchini R.S., Ganz P.A., Wieand H.S., Colangelo L.H., et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007, 25:2205-2211.
3. Extra J.M., Marty M., Brienza S., Misset J.L. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998, 25:13-22.
4. Lehky T.J., Leonard G.D., Wilson R.H., Grem J.L., Floeter M.K. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004, 29:387-392.
5. Wilson R.H., Lehky T., Thomas R.R., Quinn M.G., Floeter M.K., Grem J.L. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002, 20:1767-1774.
6. Argyriou A.A., Polychronopoulos P., Iconomou G., Chroni E., Kalofonos H.P. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 2008, 34:368-377.
7. Tournigand C., Cervantes A., Figer A., Lledo G., Flesch M., Buyse M., et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006, 24:394-400.
8. Albers J.W., Chaudhry V., Cavaletti G., Donehower R.C. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2011, CD005228.
9. Fighera M.R., Bonini J.S., de Oliveira T.G., Frussa-Filho R., Rocha J.B., Dutra-Filho C.S., et al. GM1 ganglioside attenuates convulsions and thiobarbituric acid reactive substances production induced by the intrastriatal injection of methylmalonic acid. Int J Biochem Cell Biol 2003, 35:465-473.
10. Fighera M.R., Royes L.F., Furian A.F., Oliveira M.S., Fiorenza N.G., Frussa-Filho R., et al. GM1 ganglioside prevents seizures, Na+,K+-ATPase activity inhibition and oxidative stress induced by glutaric acid and pentylenetetrazole. Neurobiol Dis 2006, 22:611-623.
11. Carolei A., Fieschi C., Bruno R., Toffano G. Monosialoganglioside GM1 in cerebral ischemia. Cerebrovasc Brain Metab Rev 1991, 3:134-157.
12. Giraldi C., Masi M.C., Manetti M., Carabelli E., Martini A. A pilot study with monosialoganglioside GM1 on acute cerebral ischemia. Acta Neurol (Napoli) 1990, 12:214-221.
13. Tan W.K., Williams C.E., Gunn A.J., Mallard E.C., Gluckman P.D. Pretreatment with monosialoganglioside GM1 protects the brain of fetal sheep against hypoxic-ischemic injury without causing systemic compromise. Pediatr Res 1993, 34:18-22.
14. Kwak D.H., Kim S.M., Lee D.H., Kim J.S., Lee S.U., Jung K.Y., et al. Differential expression patterns of gangliosides in the ischemic cerebral cortex produced by middle cerebral artery occlusion. Mol Cells 2005, 20:354-360.
15. She J.Q., Wang M., Zhu D.M., Tang M., Chen J.T., Wang L., et al. Monosialoanglioside (GM1) prevents lead-induced neurotoxicity on long-term potentiation, SOD activity, MDA levels, and intracellular calcium levels of hippocampus in rats. Naunyn Schmiedebergs Arch Pharmacol 2009, 379:517-524.
16. Chen Z.G., Lu Y.C., Zhu C., Zhang G.J., Ding X.H., Jiang J.Y. Effects of ganglioside GM1 on reduction of brain edema and amelioration of cerebral metabolism after traumatic brain injury. Chin J Traumatol 2003, 6:23-27.
17. Geisler F.H., Coleman W.P., Grieco G., Poonian D. The Sygen multicenter acute spinal cord injury study. Spine (PhilaPa 1976) 2001, 26:S87-S98.
18. Crepaldi G., Fedele D., Tiengo A., Battistin L., Negrin P., Pozza G., et al. Ganglioside treatment in diabetic peripheral neuropathy: a multicenter trial. Acta Diabetol Lat 1983, 20:265-276.
19. Leake P.A., Hradek G.T., Vollmer M., Rebscher S.J. Neurotrophic effects of GM1 ganglioside and electrical stimulation on cochlear spiral ganglion neurons in cats deafened as neonates. J Comp Neurol 2007, 501:837-853.
20. Zalish M., Lavie V., Duvdevani R., Yoles E., Schwartz M. Gangliosides attenuate axonal loss after optic nerve injury. Retina 1993, 13:145-147.
21. Porschen R., Arkenau H.T., Kubicka S., Greil R., Seufferlein T., Freier W., et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007, 25:4217-4223.
22. Adelsberger H., Quasthoff S., Grosskreutz J., Lepier A., Eckel F., Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 2000, 406:25-32.
23. Grolleau F., Gamelin L., Boisdron-Celle M., Lapied B., Pelhate M., Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001, 85:2293-2297.
24. Holmes J., Stanko J., Varchenko M., Ding H., Madden V.J., Bagnell C.R., et al. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci 1998, 46:342-351.
25. Cavaletti G., Tredici G., Petruccioli M.G., Donde E., Tredici P., Marmiroli P., et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 2001, 37:2457-2463.
26. Ta L.E., Espeset L., Podratz J., Windebank A.J. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 2006, 27:992-1002.
27. Joseph E.K., Chen X., Bogen O., Levine J.D. Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. J Pain 2008, 9:463-472.
28. Chentanez V., Thanomsridejchai N., Duangmardphon N., Agthong S., Kaewsema A., Huanmanop T., et al. Ganglioside GM1 (porcine) ameliorates paclitaxel-induced neuropathy in rats. J Med Assoc Thai 2009, 92:50-57.
29. Dong M., Chen Z.H., Wu X.Y., Wen J.Y., Lin Q., Ma X.K., et al. Efficacy of monosiaganglioside versus calcium-magnesium mixture against oxaliplatin-induced neurotoxicity. Evaluation and Analysis of Drug-use in Hospitals of China 2010, 10:3.
30. Cavaletti G., Petruccioli M.G., Marmiroli P., Rigolio R., Galbiati S., Zoia C., et al. Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat. Anticancer Res 2002, 22:4199-4204.
31. Purpura K.P., Baker H.J. Neurite induction in mature cortical neurones in feline GM1-ganglioside storage disease. Nature 1977, 266:553-554.
32. Roisen F.J., Bartfeld H., Nagele R., Yorke G. Ganglioside stimulation of axonal sprouting in vitro. Science 1981, 214:577-578.
33. Sabel B.A., Dunbar G.L., Stein D.G. Gangliosides minimize behavioral deficits and enhance structural repair after brain injury. J Neurosci Res 1984, 12:429-443.
34. Sabel B.A., DelMastro R., Dunbar G.L., Stein D.G. Reduction of anterograde degeneration in brain damaged rats by GM1-gangliosides. Neurosci Lett 1987, 77:360-366.
35. Sabel B.A., Slavin M.D., Stein D.G. GM1 ganglioside treatment facilitates behavioral recovery from bilateral brain damage. Science 1984, 225:340-342.
36. Anand P., Terenghi G., Warner G., Kopelman P., Williams-Chestnut R.E., Sinicropi D.V. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med 1996, 2:703-707.
37. Abraham R.R., Abraham R.M., Wynn V. A double blind placebo controlled trial of mixed gangliosides in diabetic peripheral and autonomic neuropathy. Adv Exp Med Biol 1984, 174:607-624.
38. Carozzi V.A., Marmiroli P., Cavaletti G. The role of oxidative stress and anti-oxidant treatment in platinum-induced peripheral neurotoxicity. Curr Cancer Drug Targets 2010, 10:670-682.
39. Cascinu S., Catalano V., Cordella L., Labianca R., Giordani P., Baldelli A.M., et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002, 20:3478-3483.
40. Karpiak S.E., Graf L., Rapport M.M. Antiserum to brain gangliosides produces recurrent epileptiform activity. Science 1976, 194:735-737.
41. Gorria M., Huc L., Sergent O., Rebillard A., Gaboriau F., Dimanche-Boitrel M.T., et al. Protective effect of monosialoganglioside GM1 against chemically induced apoptosis through targeting of mitochondrial function and iron transport. Biochem Pharmacol 2006, 72:1343-1353.
42. Maulik N., Das D.K., Gogineni M., Cordis G.A., Avrova N., Denisova N. Reduction of myocardial ischemic reperfusion injury by sialylated glycosphingolipids, gangliosides. J Cardiovasc Pharmacol 1993, 22:74-81.
43. Huang F., Dong X., Zhang L., Zhang X., Zhao D., Bai X., et al. GM1 and nerve growth factor modulate mitochondrial membrane potential and neurofilament light mRNA expression in cultured dorsal root ganglion and spinal cord neurons during excitotoxic glutamate exposure. J Clin Neurosci 2010, 17:495-500.